Cell‐Free and Concentrated Ascites Reinfusion Therapy ( CART ) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post‐Marketing Surveillance Study
ABSTRACT
Introduction
Ascites management is crucial for gynecological cancer patients requiring long‐term treatment. Cancer type‐specific differences may influence CART outcomes, but comparative data remain limited. This study evaluated CART efficacy in gynecological versus other cancers.
Methods
This subgroup analysis included 125 cancer patients undergoing 296 CART sessions at 22 Japanese centers (2014–2015). Patients were divided into gynecological cancer (Group G, n = 46) and other cancer groups (Group O, n = 79).
Results
Group G had significantly higher concurrent chemotherapy rates (41.2% vs. 12.3%, p < 0.001) and ascitic protein/albumin concentrations. Group G showed significant renal function improvements: decreased serum creatinine (0.7 ± 0.3 to 0.6 ± 0.3 mg/dL, p < 0.001), decreased BUN (17.9 ± 8.7 to 14.5 ± 9.0 mg/dL, p < 0.001), and increased eGFR (72.7 ± 24.8 to 81.3 ± 27.6 mL/min/1.73 m 2 , p < 0.001). Drainage intervals were longer in Group G (20.0 ± 13.8 vs. 11.7 ± 10.9 days, p < 0.001).
Conclusion
CART demonstrates enhanced efficacy in gynecological cancer patients, particularly improving renal function, potentially reducing chemotherapy‐related toxicity, and improving treatment tolerability.